LOBEF - Lobe Sciences Partners with Pentec Health for distribution of Altemia treatment for sickle cell disease

2023-05-17 09:15:50 ET

• Lobe Sciences ( OTCQB:LOBEF ) has entered into a commercial distribution agreement with Pentec Health, Inc. for the supply and distribution of Altemia.
• Altemia is Lobe's proprietary formulation of emulsified docosahexaenoic acid ethyl ester (DHA) concentration for patients with sickle cell disease ( SCD ).
• Pentec Health will have exclusive rights to distribute Altemia in the United States and US territories, making it available to pediatric and adult SCD patients nationwide.
• Altemia will be launched globally as a medical food to replace DHA in SCD patients, addressing an unmet need in the market.
• Previous studies have shown positive outcomes, including reduced vaso-occlusive crises and hospital visits, and improved biomarkers of inflammation for patients taking Altemia.
• Manufacturing of Altemia is conducted by Lobe's cGMP partner in the United States, with availability expected in the second half of 2023.
• The partnership with Pentec Health will facilitate a smooth launch of Altemia, leveraging their expertise in the medical food marketplace.
• The collaboration aims to make a significant impact on the lives of sickle cell disease families across the United States, providing vital treatment and support.
• Press Release

For further details see: